Immunobiology and immunotherapy of HCC

Soluble Membrane Assault Complicated: Biochemistry and Immunobiology
The soluble membrane assault complicated (sMAC, a.okay.a., sC5b-9 or TCC) is generated on activation of complement and comprises the complement proteins C5b, C6, C7, C8, C9 along with the regulatory proteins clusterin and/or vitronectin.
sMAC is a member of the MACPF/cholesterol-dependent-cytolysin superfamily of pore-forming molecules that insert into lipid bilayers and disrupt mobile integrity and performance. sMAC is a singular complement activation macromolecule as it’s comprised of a number of completely different subunits.
Up to now no complement-mediated perform has been recognized for sMAC. sMAC is current in blood and different physique fluids below homeostatic circumstances and there may be plentiful proof documenting adjustments in sMAC ranges throughout an infection, autoimmune illness and trauma.
Regardless of a long time of scientific curiosity in sMAC, the mechanisms regulating its formation in wholesome people and its organic capabilities in each well being and illness stay poorly understood.
Right here, we assessment the structural variations between sMAC and its membrane counterpart, MAC, and study sMAC immunobiology with respect to its presence in physique fluids in well being and illness. Lastly, we talk about the diagnostic potential of sMAC for diagnostic and prognostic functions and potential utility as a companion diagnostic.
jmicrobiol
jmicrobiol

AAV5-GFP Control Virus

AAV-305 50 ?L
EUR 1221.6
Description: GFP control virus of AAV serotype 5.

AAV6-GFP Control Virus

AAV-306 50 ?L
EUR 1221.6
Description: GFP control virus of AAV serotype 6.

AAV2 Null Control Virus

AAV-352 50 ?L
EUR 1221.6
Description: Null (empty) control virus of AAV serotype 2.

AAV3 Null Control Virus

AAV-353 50 ?L
EUR 1221.6
Description: Null (empty) control virus of AAV serotype 3.

AAV4 Null Control Virus

AAV-354 50 ?L
EUR 1221.6
Description: Null (empty) control virus of AAV serotype 4.

AAV5 Null Control Virus

AAV-355 50 ?L
EUR 1221.6
Description: Null (empty) control virus of AAV serotype 5.

AAV6 Null Control Virus

AAV-356 50 ?L
EUR 1221.6
Description: Null (empty) control virus of AAV serotype 6.

AAV2-Cre Control Virus

AAV-310 50 ?L
EUR 1221.6
Description: Cre control virus of AAV serotype 2.

AAV3-Cre Control Virus

AAV-313 50 ?L
EUR 1221.6
Description: Cre control virus of AAV serotype 3.

AAV4-Cre Control Virus

AAV-314 50 ?L
EUR 1221.6
Description: Cre control virus of AAV serotype 4.

AAV5-Cre Control Virus

AAV-315 50 ?L
EUR 1221.6
Description: Cre control virus of AAV serotype 5.

AAV6-Cre Control Virus

AAV-316 50 ?L
EUR 1221.6
Description: Cre control virus of AAV serotype 6.

AAV2-Luc Control Virus

AAV-320 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 2.

AAV3-Luc Control Virus

AAV-323 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 3.

AAV4-Luc Control Virus

AAV-324 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 4.

AAV5-Luc Control Virus

AAV-325 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 5.

AAV6-Luc Control Virus

AAV-326 50 ?L
EUR 1221.6
Description: Luciferase control virus of AAV serotype 6.

AAV2-LacZ Control Virus

AAV-342 50 ?L
EUR 1221.6
Description: LacZ control virus of AAV serotype 2.

AAV3-LacZ Control Virus

AAV-343 50 ?L
EUR 1221.6
Description: LacZ control virus of AAV serotype 3.

AAV4-LacZ Control Virus

AAV-344 50 ?L
EUR 1221.6
Description: LacZ control virus of AAV serotype 4.

AAV5-LacZ Control Virus

AAV-345 50 ?L
EUR 1221.6
Description: LacZ control virus of AAV serotype 5.

AAV6-LacZ Control Virus

AAV-346 50 ?L
EUR 1221.6
Description: LacZ control virus of AAV serotype 6.

saCas9 Nuclease AAV Virus (AAV1)

K208 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

scAAV1-GFP Control Virus

AAV-331 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 1.

scAAV2-GFP Control Virus

AAV-332 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 2.

scAAV3-GFP Control Virus

AAV-333 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 3.

scAAV4-GFP Control Virus

AAV-334 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 4.

scAAV5-GFP Control Virus

AAV-335 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 5.

scAAV6-GFP Control Virus

AAV-336 50 ?L
EUR 1221.6
Description: Self-complementary GFP control virus of AAV serotype 6.

Lenti-III-UBC-GFP Control Virus

LV027 4 x 500 ul
EUR 195

Lenti-III-PGK-GFP Control Virus

LV028 4 x 500 ul
EUR 195

Lenti-III-EF1alpha-GFP Control Virus

LV046 4 x 500 ul
EUR 195

pCDH-Cuo-RFP-T2A-GFP (positive control virus)

QM350VA-1 >1 x 10^6 IFUs
EUR 573

HSV-1 Virus Control Stock

20-4810020 Single Use, 400 µL, shipped frozen Ask for price
Description: Genetically Engineered BHK Cells

HSV-2 Virus Control Stock

20-4820020 Single Use, 400 µL, shipped frozen Ask for price
Description: Genetically Engineered BHK Cells

Zika Virus NS1 Control Antigen

BA149R01 1 mg
EUR 947

Measles Virus IgG Control Serum

C102G 3 mL
EUR 105

Measles Virus IgM Control Serum

C102M 3 mL
EUR 105

Rubella Virus IgG Control Serum

C129G 3 mL
EUR 105

Rubella Virus IgM Control Serum

C129M 3 mL
EUR 105

Lenti-III-PGK-Luc Control Virus

LV088 4 x 500 ul
EUR 195

pRedTK-CMV Virus [positive control]

SR10052VA-1 >2 x 10^6 IFUs
EUR 625

pRedZeo-CMV Virus [positive control]

SR10046VA-1 >2 x 10^6 IFUs
EUR 625

pGreenZeo-CMV Virus [positive control]

SR501VA-1 >2 x 10^6 IFUs
EUR 608

Zika Virus Human IgA Assay Control

BC149A 1 mL
EUR 105

Zika Virus Human IgG Assay Control

BC149G 1 mL
EUR 105

Zika Virus Human IgM Assay Control

BC149M 1 mL
EUR 105

pGreenZeo-mCMV Virus [negative control]

SR500VA-1 >2 x 10^6 IFUs
EUR 608

Dengue Virus Human IgG Assay Control

BC114G 1 mL
EUR 105

Dengue Virus Human IgM Assay Control

BC114M 1 mL
EUR 105

Influenza A Virus IgA Control Serum

C1231A 3 mL
EUR 105

Influenza A Virus IgG Control Serum

C1231G 3 mL
EUR 105

Influenza A Virus IgM Control Serum

C1231M 3 mL
EUR 105

Influenza B Virus IgA Control Serum

C1232A 3 mL
EUR 105

Influenza B Virus IgG Control Serum

C1232G 3 mL
EUR 105

Influenza B Virus IgM Control Serum

C1232M 3 mL
EUR 105

Mumps Virus Nucleoprotein Control Antigen

BA103R01 1 mg
EUR 1016

Measles Virus Nucleoprotein Control Antigen

BA102R01 1 mg
EUR 1016

Mumps/Parotitis Virus IgG Control Serum

C103G 3 mL
EUR 105

Mumps/Parotitis Virus IgM Control Serum

C103M 3 mL
EUR 105

EZ‐Seneca Valley Virus A Control Set

TC-9080-096 each
EUR 90

Chikungunya Virus Human IgG Assay Control

BC148G 1 mL
EUR 105

Chikungunya Virus Human IgM Assay Control

BC148M 1 mL
EUR 105

Adeno-Associated Virus 1 / AAV1 (intact particle) mouse monoclonal antibody, clone ADK1a, Purified

BM5093 50 µg Ask for price

Varicella-Zoster Virus IgA Control Serum

C104A 3 mL
EUR 105

Varicella-Zoster Virus IgG Control Serum

C104G 3 mL
EUR 105

Varicella-Zoster Virus IgM Control Serum

C104M 3 mL
EUR 105

West Nile Virus Human IgG Assay Control

BC141G 1 mL
EUR 105

West Nile Virus Human IgM Assay Control

BC141M 1 mL
EUR 105

Virus-Like Particles (VLPs) isotype control

CSB-MP3838 11453 mg Ask for price

Parainfluenza Virus Human IgA Assay Control

BC126A 1 mL
EUR 105

Parainfluenza Virus Human IgG Assay Control

BC126G 1 mL
EUR 105

Herpes Simplex Virus 1 IgM Control Serum

C1051M 3 mL
EUR 105

Herpes Simples Virus 2 IgM Control Serum

C1052M 3 mL
EUR 105

Epstein-Barr Virus EA IgG Control Serum

C1363G 3 mL
EUR 105

Respiratory Syncytial Virus IgA Control Serum

C113A 3 mL
EUR 105

Respiratory Syncytial Virus IgG Control Serum

C113G 3 mL
EUR 105

Epstein-Barr Virus VCA IgG Control Serum

C1361G 3 mL
EUR 105

Epstein-Barr Virus VCA IgM Control Serum

C1361M 3 mL
EUR 105

Dengue Virus superior Human IgM Assay Control

BC1141M 1 mL
EUR 105

Influenza A virus HA Control/blocking peptide

AB-23091-P 100ug
EUR 196.8

Adeno-Associated Virus 1 / AAV1 (intact particle) mouse monoclonal antibody, clone ADK1a, Biotin, Purified

BM5093B 750 µl Ask for price

Herpes Simplex Virus 1 gP IgG Control Serum

C1051G 3 mL
EUR 105

Herpes Simplex Virus 2 gP IgG Control Serum

C1052G 3 mL
EUR 105

Herpes Simplex Virus 1+2 IgA Control Serum

C105A 3 mL
EUR 105

Herpes Simplex Virus 1+2 IgG Control Serum

C105G 3 mL
EUR 105

Herpes Simplex Virus 1+2 IgM Control Serum

C105M 3 mL
EUR 105

Virus-Like Particle (VLP) Protein Isotype Control

VLP-N5213 30ug
EUR 428
Description: VLP isotype control (VLP-N5213) is expressed from human 293 cells (HEK293).

Tick-Borne Encephalitis Virus IgG Control Serum

C112G 3 mL
EUR 105

Tick-Borne Encephalitis Virus IgM Control Serum

C112M 3 mL
EUR 105

Epstein-Barr Virus EBNA-1 IgG Control Serum

C1362G 3 mL
EUR 105

Vaccinia virus Complement control protein C3 (VACWR025)

1-CSB-YP302389VAI
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • Ask for price
  • 100ug
  • 10ug
  • 1MG
  • 200ug
  • 500ug
  • 50ug
Description: Recombinant Vaccinia virus Complement control protein C3(VACWR025) expressed in Yeast

AAV1 SaCas9

78479 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_Cas9 is an endonuclease enzyme that introduces a double stranded break into the DNA when recruited to a specific DNA sequence by the sgRNA (single guide RNA). This double stranded break is repaired in mammalian cells either through Non-Homologous End Joining or Homologous Recombination. Non-Homologous End Joining often results in the deletion or insertion of several base pairs at the cut site, which, when resulting in a frameshift, causes the functional inactivation of the gene._x000D_SaCas9 (Staphylococcus aureus CRISPR-associated protein 9) has demonstrated high cutting efficiency in mammalian cells, and its smaller size makes it ideal for packaging into AAV. SaCas9 recognizes a longer protospacer adjacent motif (PAM) site, 5'-NNGRRT-3', than the more traditional SpCas9 (Streptococcus pyogenes CRISPR-associated protein 9). These AAV particles constitutively express SaCas9 under the control of a CMV promoter.

pGreenFire 2.0-CMV positive control virus (pGF2-CMV-rFluc-T2A-GFP-mPGK-Puro)

TR410VA-P >2 x 10^6 IFUs
EUR 632

AAV1 ZsGreen

78443 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV1 particles constitutively express ZsGreen under a CMV promoter. ZsGreen is a human codon-optimized variant of the green fluorescent protein isolated from reef coral (Zoanthus sp). It has been engineered for higher expression in mammalian cells and is up to four times brighter than enhanced GFP (eGFP). ZsGreen expression and AAV1 transduction efficiency can easily be verified and optimized by fluorescence microscopy or flow cytometry. ZsGreen has an excitation wavelength of 493 nm and an emission wavelength of 505 nm.

pGreenPuro Scramble Hairpin Control - Virus (for shRNAs and miRZips)

MZIP000-VA-1 >1 x 10^6 IFUs
EUR 652

AAV1 antibody

10R-2473 5 mL
EUR 550.8
Description: Mouse monoclonal AAV1 antibody

pGreenFire 2.0-mCMV negative control virus (pGF2-mCMV-rFluc-T2A-GFP-mPGK-Puro)

TR411VA-P >2 x 10^6 IFUs
EUR 632

AAV1 Luciferase

78452 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV particles constitutively express the firefly (Photinus pyralis) luciferase under the control of a CMV promoter.

Baboon Anti-Rabies Virus IgG antiserum negative control

600-070-03N 1 ml
EUR 196.8

Baboon Anti-Rabies Virus IgG antiserum positive control

600-070-04P 1 ml
EUR 270

Camelpox virus H3L/p35 protein control for western blot

CPOX11-C 100 ul
EUR 343.2

Zika Virus prM Protein (African) control for Western blot

ZPRM11-C 100 ul
EUR 343.2

Recombinant Polyoma Virus (KV, Pneumotropic virus) Capsid Protein 1 (VP1) control for Western blot

KVP14-C 100 ul
EUR 343.2

NATtrol BK Virus External Run Control, Low (6 X 1 mL)

NATBK-ERCL 6 X 1 mL
EUR 360

Mayaro virus (MAYV) 6K Protein control for Western Blotting

MAYV51-C 100 ug
EUR 343.2

Mayaro virus (MAYV) E3 protein control for Western Blotting

MAYV61-C 100 ul
EUR 343.2

Simian virus 5 (starin W3) P/V Control/blocking peptide

AB-23077-P 100ug
EUR 196.8

Fluorescent Virus-Like Particle (VLP) Protein Isotype Control

VLP-NF2P4 30ug
EUR 428
Description: Fluorescent VLP isotype control (VLP-NF2P4) is expressed from human 293 cells (HEK293).

NATtrol Zika Virus, External Run Control, Low (6 x 1 mL)

NATZIKV-ERCL 6 x 1 mL
EUR 350

Mayaro virus (MAYV) nsP1 protein control for Western Blotting

MAYV41-C 100 ul
EUR 343.2

Purified Nipah virus Glycoprotein control for Western Blotting

NIV11-C 100 ul
EUR 343.2

NATtrol BK Virus External Run Control, Medium (6 X 1 mL)

NATBK-ERCM 6 X 1 mL
EUR 438

Purified Nipah virus Nucleoprotein control for Western Blotting

NIV21-C 100 ul
EUR 270

Human Anti-Mumps Virus (parotitis) IgG negative control serum

520-100-01N 1 ml
EUR 196.8

Human Anti-Mumps Virus (parotitis) IgG positive control serum

520-100-02P 1 ml
EUR 270

Mouse Anti-Mumps Virus (parotitis) IgG negative control serum

520-130-05N 1 ml
EUR 196.8

Mouse Anti-Mumps Virus (parotitis) IgG positive control serum

520-130-06P 1 ml
EUR 270

Mayaro virus (MAYV) Capsid Protein control for Western Blotting

MAYV31-C 100 ul
EUR 343.2

NATtrol Zika Virus, External Run Control, Medium (6 x 1 mL)

NATZIKV-ERCM 6 x 1 mL
EUR 425

Recombinant Vaccinia virus Complement control protein C3 (VACWR025)

CSB-YP302389VAI 6104 mg Ask for price

Recombinant Vaccinia virus Complement control protein C3(VACWR025)

AP74192 1mg
EUR 3389

Monkey Anti-Mumps Virus (parotitis) IgG negative control serum

520-160-03N 1 ml
EUR 196.8

Monkey Anti-Mumps Virus (parotitis) IgG positive control serum

520-160-04P 1 ml
EUR 270

Cynos Monkey Anti-Rabies Virus IgG antiserum positive control

600-070-06P 1 ml
EUR 270

Rabies Virus Glycoprotein (~58 kda, RVG) control for western blot

RBVGP11-C 100 ul
EUR 343.2

Bovine Lumpy skin disease virus (LSDV) control for western blot

LSDV11-C 100 ul
EUR 343.2

Rhesus Monkey Anti-Rabies Virus IgG antiserum negative control

600-070-01N 1 ml
EUR 196.8

Rhesus Monkey Anti-Rabies Virus IgG antiserum positive control

600-070-02P 1 ml
EUR 270

Camel Anti-Camelpox virus H3L/p35 IgG negative control serum

AE-311170-01N 1 ml
EUR 196.8

Camel Anti-Camelpox virus H3L/p35 IgG positive control serum

AE-311170-02P 1 ml
EUR 270

OPEF01337-1ML - Epstein-Barr Virus (EBV) Negative Control Extract

OPEF01337-1ML 1ml
EUR 174

Control/Blocking peptide for Tobacco Mosaic Virus Movement Protein

TMVMP11-P 100 ug
EUR 196.8

OPEF01337-25ML - Epstein-Barr Virus (EBV) Negative Control Extract

OPEF01337-25ML 25ml
EUR 2901

Varicella Zoster Virus (VZV) Envelope Glycoprotein E Control Antigen

BA104R02 1 mg
EUR 953

saCas9 Nuclease AAV Virus (AAV10)

K217 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV11)

K218 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

AAV1 ELISA Kit

55R-PROPRAAV1 96 tests
EUR 1153
Description: ELISA kit for detection of AAV1 in the research laboratory

Monkey (Cynomolgous) Anti-Rabies Virus IgG antiserum negative control

600-070-05N 1 ml
EUR 196.8

Influenza A virus (H5N1) matrix protein 2 Control/blocking peptide

M2E15-P 100 ug
EUR 196.8

Influenza A virus (H1N1) matrix protein 2 Control/blocking peptide

M2E16-P 100 ug
EUR 196.8

Influenza A virus (H9N2) matrix protein 2 Control/blocking peptide

M2E17-P 100 ug
EUR 196.8

Bovine Anti-Lumpy skin disease virus (LSDV) negative control serum

RV-500700-01N 1 ml
EUR 196.8

Bovine Anti-Lumpy skin disease virus (LSDV) positive control serum

RV-500700-02P 1 ml
EUR 270

Respiratory Syncytial Virus (RSV) Rapid Test Control Pack (2 X 1.5mL)

KZMC034 RSV Rapid Test Control Pack
EUR 59

NATtrol Zika Virus (PRVABC59), External Run Control, Medium (6 x 1.0mL)

NATZIKV(PRV)-ERCM 6 x 1.0mL
EUR 425

NATtrol Zika Virus (PRVABC59), External Run Control, Low (6 x 1.0 mL)

NATZIKV(PRV)-ERCL 6 x 1.0 mL
EUR 350

Bovine Viral Diarrhea Virus 2 E2 (BVDV2E2) IgG negative control serum

RV-500100-03N 1 ml
EUR 196.8

saCas9 Nuclease AAV Virus (AAV4)

K211 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV5)

K212 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV2)

K209 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV3)

K210 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV6)

K213 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV7)

K214 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV8)

K215 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

saCas9 Nuclease AAV Virus (AAV9)

K216 2 x 250 µl, 1 x 10^9 GC/ml, Titer: 1 x 10^9 GC/ml
EUR 375
Description: This AAV vector expresses the Cas9 orthologue from Staphylococcus Aureus (saCas9). saCas9 is ~1 kb shorter than spCas9, allowing it to be efficiently packaged in AAV Virus. Furthermore, the saCas9 enzyme recognizes a longer PAM sequence than spCas9, and thus has greater editing specificity.AAV has low immunogenicity and broad host range, making it an ideal choice for both in vivo and in vitro applications. Use this saCas9-expressing AAV virus with a target-specific saCas9-compatible sgRNA for highly specific and efficient genome editing.

Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG negative control serum

RV-500200-01N 1 ml
EUR 196.8

Bovine Viral Diarrhea Virus (BVDV1-3) Erns IgG positive control serum

RV-500200-02P 1 ml
EUR 270

AAV1 Luciferase-eGFP

78461 50 µl x 2
EUR 545
Description: Adeno-Associated Virus Serotype 1 (AAV1) exhibits high homology with other AAV serotypes. AAV1 efficiently transduces muscle tissue, as determined by a region of the capsid protein VP1 (amino acids 350 to 430) which functions as a major determinant of tissue tropism._x000D_These AAV1 particles constitutively express the firefly (Photinus pyralis) luciferase and eGFP genes connected via a T2A linker, under the control of a CMV promoter. The T2A self-cleaving peptide (derived from Thosea asigna virus 2A) leads to the efficient cleavage of the transcript, and expression of luciferase and eGFP as two separate proteins.

Bovine Viral Diarrhea Virus 3 E2 (BVDV3- E2) IgG positive control serum

RV-500100-06P 1 ml
EUR 270

Immunobiology and immunotherapy of HCC: highlight on innate and innate-like immune cells

Immune-based therapies equivalent to immune checkpoint inhibitors have revolutionized the systemic therapy of assorted most cancers varieties. The therapeutic software of monoclonal antibodies focusing on inhibitory pathways equivalent to programmed cell death-1(PD-1)/programmed cell demise ligand 1 (PD-L1) and CTLA-Four to cells of the adaptive immune system has just lately been proven to generate significant enchancment within the medical consequence of hepatocellular carcinoma (HCC).
Nonetheless, present immunotherapeutic approaches induce sturdy responses in solely a subset of HCC sufferers. Since immunologic mechanisms equivalent to continual irritation as a consequence of continual viral hepatitis or alcoholic and nonalcoholic fatty liver illness play an important position within the initiation, improvement, and development of HCC, it is very important perceive the underlying mechanisms shaping the distinctive tumor microenvironment of liver most cancers.
The liver is an immunologic organ with massive populations of innate and innate-like immune cells and is uncovered to bacterial, viral, and fungal antigens via the gut-liver axis. Right here, we summarize and spotlight the position of those cells in liver most cancers and suggest methods to therapeutically goal them.
We additionally talk about present immunotherapeutic methods in HCC and description current advances in our understanding of how the therapeutic potential of those brokers is likely to be enhanced.

Peripheral blood T lymphocytosis in thymoma: an perception into immunobiology

Objective: Peripheral blood T lymphocytosis (PBTL) is a uncommon, but poorly understood manifestations of thymoma, which is postulated to be linked with autoimmune/paraneoplastic manifestations equivalent to myasthenia gravis (MG), pure purple cell aplasia (PRCA), and so on.; extra generally encountered on this neoplasm.

Methodology: We goal to explain the flowcytometric immunophenotypic information of PBTL in a 43-year-old male; 6 months after profitable completion of chemoradiotherapy (CT/RT) for a big, invasive, and metastatic sort B1 thymoma; and current a complete assessment of all such circumstances reported over final 42 years (N = 21) (1977-2019).

Consequence: A bigger dimension of the tumors (≥ 10 cm), presence of native invasion and/or distant metastasis, and sort B (cortical or lymphocyte wealthy) histology have been extra prone to be related to PBTL.

Tumors related to MG/PRCA (N = 9/21) are inclined to have decrease PBTL in comparison with these with out such manifestations; and PBTL subsided following thymectomy with or with out CT/RT. Immunophenotypic evaluation of PB revealed a CD8 + > CD4 + mature (naïve) polyclonal T cells resembling late cortical thymocytes.

Conclusion: Thymic intratumoral microenvironment may affect prevalence PBTL which will have a pathophysiologic hyperlink to the improvement of autoimmune manifestations. Immunophenotypic traits of peripheral blood lymphoid cells must be the clue for correct characterization and to keep away from a misdiagnosis of a lymphoproliferative neoplasm.
Immunobiology of Acquired Resistance to Ticks
Ticks are blood-sucking arthropods of nice significance within the medical and veterinary fields worldwide. They’re thought-about second solely to mosquitos as vectors of pathogenic microorganisms that may trigger severe infectious issues, such as Lyme borreliosis and tick-borne encephalitis.
Onerous (Ixodid) ticks feed on host animals for a number of days and inject saliva along with pathogens to hosts throughout blood feeding. Some animal species can purchase resistance to blood-feeding by ticks after a single or repeated tick infestation, leading to decreased weights and numbers of engorged ticks or the demise of ticks in subsequent infestations. Importantly, this acquired tick resistance (ATR) can scale back the danger of pathogen transmission from pathogen-infected ticks to hosts.
That is the premise for the event of tick antigen-targeted vaccines to forestall tick infestation and tick-borne ailments. Accumulation of basophils is detected within the tick re-infested pores and skin lesion of animals exhibiting ATR, and the ablation of basophils abolishes ATR in mice and guinea pigs, illustrating the essential position for basophils within the expression of ATR.
On this assessment article, we offer a complete overview of current advances in our understanding of the mobile and molecular mechanisms accountable for the event and manifestation of ATR, with a specific concentrate on the position of basophils.
T-cell immunobiology and cytokine storm of COVID-19
2019 coronavirus illness (COVID-19) presents as a newly acknowledged pneumonia and will quickly progress into acute respiratory misery syndrome which has caused a worldwide pandemic. Till now, no healing remedy has been strongly beneficial for COVID-19 apart from personalised supportive care.
T cells and virus-specific T cells are important to guard in opposition to virus an infection, together with COVID-19. Delayed immune reconstitution (IR) and cytokine storm (CS) stay severe obstacles for the remedy of COVID-19.
Most COVID-19 sufferers, particularly amongst aged sufferers, had marked lymphopenia and elevated neutrophils, however T cell counts in extreme COVID-19 sufferers surviving the illness step by step restored later.
Elevated pro-inflammatory cytokines, notably IL-6, IL-10, IL-2, and IL-17, and exhausted T cells are present in peripheral blood and the lungs. It means that Thymosin α1 and adoptive COVID-19-specific T cells may enhance IR whereas convalescent plasma, IL-6 blockade, mesenchymal stem cells, and corticosteroids may suppress CS.
Extra medical research on this subject worldwide are urgently warranted to pave the best way for remedy of COVID-19 sooner or later.

Add a Comment

Your email address will not be published. Required fields are marked *